{"nctId":"NCT00348881","briefTitle":"Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants","startDateStruct":{"date":"2006-06"},"conditions":["Diphtheria","Tetanus","Pertussis","Hepatitis B","Influenza"],"count":2133,"armGroups":[{"label":"Group 1: DTaP-Hep B-PRP-T + OPV vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: DTaP-HB-PRP~T combined vaccine","Biological: Oral poliomyelitis vaccine (OPV)"]},{"label":"Group 2: Tritanrix-HepB/Hib™ + OPV vaccine","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Tritanrix-HepB/Hib™ vaccine","Biological: Oral poliomyelitis vaccine (OPV)"]}],"interventions":[{"name":"DTaP-HB-PRP~T combined vaccine","otherNames":[]},{"name":"Tritanrix-HepB/Hib™ vaccine","otherNames":[]},{"name":"Oral poliomyelitis vaccine (OPV)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAt Screening:\n\n* 0 to 3 day old infants\n* Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg\n* Apgar score ≥ 7 at three minutes after birth\n* Informed consent form signed by one parent or legal representative if appropriate (independent witness mandatory if parent is illiterate)\n\nAt Inclusion:\n\n* Six weeks of age\n* Received a dose of Hepatitis B (HB) in the first three days of life\n* Able to attend all scheduled visits and to comply with all trial procedures.\n\nExclusion Criteria:\n\nAt Screening:\n\n* Illness at a stage that could interfere with trial conduct or completion\n* Any vaccination before HB vaccination (except bacille Calmette-Guérin \\[BCG\\] given at birth)\n* Vaccination planned in the 4 to 6 weeks following the first trial vaccination (except BCG if not given at birth)\n* Acute illness on the day of screening.\n\nAt Screening and at Inclusion:\n\n* Blood or blood-derived products received since birth\n* Planned participation in another clinical trial during the present trial period\n* Mother known as seropositive to Human immunodeficiency virus (HIV) or Hepatitis C, or as carrying the HB surface antigen (HBsAg)\n* Known thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination\n* Known hypersensitivity to any component of any vaccine to be used in the trial (including neomycin and polymixin B)\n\nAt Inclusion:\n\n* Non-trial vaccine administered since birth, except Bacille Calmette-Guérin (BCG)\n* Participation in another clinical trial before the first trial vaccination\n* Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroid therapy\n* Systemic hypersensitivity to any of the vaccine components or history of a life threatening reaction to the trial vaccine or a vaccine containing the same substances\n* Chronic illness at a stage that could interfere with trial conduct or completion\n* Vaccination other than with the study vaccines planned in the 12 weeks following inclusion\n* Documented history of pertussis, tetanus, diphtheria, polio, H. influenza type b, or HB infection (confirmed clinically, serologically, or microbiologically)\n* History of seizures\n* Febrile (rectal temperature ≥ 38.0°C) or acute illness on the day of inclusion.","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"50 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Seroprotection was assessed by means of radioimmunoassay (RIA) for anti-Hepatitis B (Hep Bs) and anti-PRP antibodies, enzyme immunoassay (EIA) for anti-Tetanus, and serum neutralization (SN) for anti-Diphtheria.\n\nSeroprotection was defined as titers ≥ 10 mIU/mL for anti-Hep Bs; ≥ 0.15 μg/mL for anti-PRP; ≥ 0.01 IU/mL for anti-Tetanus and anti-Diphtheria at 30 days after the third vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"119","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Immunogenicity was assessed by means of radioimmunoassay (RIA) for anti-Hepatitis B (Hep Bs) and anti-PRP antibodies; enzyme immunoassay (EIA) for anti-Tetanus; serum neutralization (SN) for anti-Diphtheria; and enzyme-linked immunosorbent assay (ELISA) for anti-Pertusiss (PT) and anti-Filamentous Hemagglutinin (FHA) titers at Day 150, 1 month after the third vaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"464","spread":null},{"groupId":"OG001","value":"343","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.025","spread":null},{"groupId":"OG001","value":"0.023","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"81.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.7","spread":null},{"groupId":"OG001","value":"9.17","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Observed High Fever During the 7-Day After Vaccination With DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/ Hib™ Concomitantly With OPV.","description":"Occurence of at least one high fever episode (≥ 39.6ºC rectal temperature equivalent) observed within 7 days after any of the three injections.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting At Least One Solicited Injection Site Reaction or Systemic Reactions Following Each Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV","description":"Solicited injection site reactions: Pain, Erythema, and Swelling; Solicited systemic reactions; Fever (temperature), Vomiting, Abnormal Crying, Drowsiness, Loss of Appetite, and irritability.\n\nGrade 3 reactions are defined as: Pain - cries when injected limb is moved; Erythema and Swelling - ≥ 5cm; Fever - rectal temperature ≥ 39.6ºC; Vomiting - ≥6 episodes per 24 hours; Crying - inconsolable crying for \\>3 hours; Somnolence - sleeping most of the time or difficulty to wake up; Anorexia - refuses ≥3 feeds; and Irritability - inconsolable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1092","spread":null},{"groupId":"OG001","value":"636","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344","spread":null},{"groupId":"OG001","value":"295","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"958","spread":null},{"groupId":"OG001","value":"573","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"751","spread":null},{"groupId":"OG001","value":"463","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"616","spread":null},{"groupId":"OG001","value":"407","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"794","spread":null},{"groupId":"OG001","value":"497","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"543","spread":null},{"groupId":"OG001","value":"353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"448","spread":null},{"groupId":"OG001","value":"320","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"408","spread":null},{"groupId":"OG001","value":"283","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"719","spread":null},{"groupId":"OG001","value":"503","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"576","spread":null},{"groupId":"OG001","value":"423","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"438","spread":null},{"groupId":"OG001","value":"343","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"288","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"523","spread":null},{"groupId":"OG001","value":"394","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null},{"groupId":"OG001","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"187","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"266","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"567","spread":null},{"groupId":"OG001","value":"381","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"431","spread":null},{"groupId":"OG001","value":"301","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"193","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"673","spread":null},{"groupId":"OG001","value":"360","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"527","spread":null},{"groupId":"OG001","value":"282","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"368","spread":null},{"groupId":"OG001","value":"216","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"255","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"396","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235","spread":null},{"groupId":"OG001","value":"159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"201","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"945","spread":null},{"groupId":"OG001","value":"539","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"823","spread":null},{"groupId":"OG001","value":"471","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"499","spread":null},{"groupId":"OG001","value":"331","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"369","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":1425},"commonTop":["Solicited injection site Pain","Irritability","Solicited injection site Swelling","Solicited injection site Erythema","Somnolence"]}}}